
Cumberland Pharmaceuticals Inc.: updates and filings
Price
$5.21
November 16, 2026Market cap $78M
What Ploutos Investor adds for Cumberland Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 25% since Aug 7, 2026, when the 10-Q these figures come from was filed ($7.80 then, $5.88 on Nov 13, 2026). The figures date from before that move.10-Q
- The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 8, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
October 2026
September 2026
August 2026
July 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Oct 26, 2026Regulation FD disclosure, other material eventsForm8-K
- Oct 23, 2026Other material eventsForm8-K
- Sep 11, 2026Shareholder vote (amendment)Form8-K/A
- Aug 28, 2026Regulation FD disclosureForm8-K
- Aug 7, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 4, 2026Results of operationsForm8-K
- Jul 13, 2026Other material eventsForm8-K
- Jul 1, 2026Material agreement entered, material agreement ended, acquisition or disposal of assets, officer or director change, other material eventsForm8-K
- Jun 25, 2026Shareholder voteForm8-K
- May 26, 2026Merger meeting proxy statementFormDEFM14A
- May 15, 2026FilingFormPREM14A
- May 8, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Results of operationsForm8-K
- Apr 24, 2026Shareholder voteForm8-K
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 23, 2026Material agreement entered, Regulation FD disclosure, other material eventsForm8-K
- Mar 12, 2026Annual report to shareholdersFormARS
- Mar 9, 2026Additional annual meeting materialFormDEFA14A
- Mar 9, 2026Annual meeting proxy statementFormDEF 14A
- Mar 9, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 3, 2026Results of operationsForm8-K
- Feb 9, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 4, 2026Other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Oct 26, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Oct 23, 2026 | 8-K | Other material events | Document |
| Sep 11, 2026 | 8-K/A | Shareholder vote (amendment) | Document |
| Aug 28, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 7, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 4, 2026 | 8-K | Results of operations | Document |
| Jul 13, 2026 | 8-K | Other material events | Document |
| Jul 1, 2026 | 8-K | Material agreement entered, material agreement ended, acquisition or disposal of assets, officer or director change, other material events | Document |
| Jun 25, 2026 | 8-K | Shareholder vote | Document |
| May 26, 2026 | DEFM14A | Merger meeting proxy statement | Document |
| May 15, 2026 | PREM14A | Filing | Document |
| May 8, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| Apr 24, 2026 | 8-K | Shareholder vote | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 23, 2026 | 8-K | Material agreement entered, Regulation FD disclosure, other material events | Document |
| Mar 12, 2026 | ARS | Annual report to shareholders | Document |
| Mar 9, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 9, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 9, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 3, 2026 | 8-K | Results of operations | Document |
| Feb 9, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 4, 2026 | 8-K | Other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 2, 2002.
The full analysis
What do Cumberland Pharmaceuticals's filings show?
The filings are where every one of Cumberland Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.